argenx stock broadens growth plan at Jefferies healthcare conference
Published on 11/17/2026 at 10:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGrowth plan reaches beyond VYVGART
- Management reiterated its Vision 2030 goal of reaching 50,000 patients across 10 labeled indications.
- argenx expects up to five potential launches next year, including new myasthenia gravis indications and an auto-injector.
- The company is expanding its pipeline across FcRn, celiac disease, combination therapy and other immunology areas.
On Tuesday, November 17, 2026, Investing.com reported on argenx management's growth strategy presented at the Jefferies Global Healthcare Conference. Executives described a business that remains centered on VYVGART while adding new indications, formulations and pipeline programs beyond the core FcRn franchise.
argenx stock traded at 864.40 euros on Lang & Schwarz at 10:08 CET on Tuesday, November 17.
Five potential launches ahead
Management said argenx is preparing for as many as five potential launches next year. The opportunities include pediatric and ocular myasthenia gravis expansions, an indication for immune-mediated necrotizing myopathy, an auto-injector version of VYVGART and empasiprubart in multifocal motor neuropathy.
The company expects the planned launches to add to its commercial base while broadening the use of its medicines. The IMNM program is supported by the ALKIVIA study, whose results management said support a filing, while empasiprubart remains tied to an upcoming Phase 3 readout in multifocal motor neuropathy.
Vision 2030 remains the anchor
Executives reiterated argenx's Vision 2030 objective of reaching 50,000 patients worldwide across 10 labeled indications. Management said generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy should provide most of the patient growth, with additional contributions from new indications and products.
The company also said it has 10 clinical-stage assets in development. That pipeline is intended to extend growth beyond VYVGART through next-generation FcRn candidates, celiac disease research, combination approaches and additional immunology programs.
Combination therapy enters focus
A central theme at the conference was the potential use of combination therapy in autoimmune disease. Argenx is studying empasiprubart with VYVGART in patients who respond only partly to VYVGART, using the ADAPT-Forward platform to test combinations and identify candidates for further development.
Management said initial data from the first generalized myasthenia gravis cohort are expected next year. Executives also indicated that strong results could support a rapid move toward Phase 3 development, although the clinical data will determine the next step.
Longer-term FcRn strategy
Argenx is developing the long-acting FcRn candidates ARGX-213 and ARGX-124 as part of its strategy for the next phase of the franchise. Management described monthly dosing as a goal for ARGX-213 and said the programs could provide flexibility across therapeutic areas, dosing intervals and pricing models as VYVGART matures.
The company is also continuing work on celiac disease through the program acquired with Forte. Management said the CD122 approach, which addresses both the IL-15 and IL-2 pathways, could offer a differentiated mechanism, while longer-term clinical exposure remains an important development milestone.
The Dutch market backdrop is followed through the AEX.
Company facts
argenx company facts
- Company: argenx SE
- ISIN: NL0010832176
- Lang & Schwarz quote: 864.40 euros at 10:08 CET on November 17, 2026
Further developments around the pipeline, clinical milestones and commercial expansion can be followed in More news and analyses on argenx stock.
